Present a bibliometric analysis of 1432 publications in Indian research in atypical antipsychotic drugs during 1998-2013, using publications indexed in Scopus database. The study identifi ed the global publication share and rank of Indian research output among the 15 most productive countries and examined the distribution of citations of the Indian research output, the share of international collaborative publications in Indian publication output and identifi cation of the leading India's collaborating partners, the distribution of Indian research output by broad subject areas, by individual drugs and by disease; publication productivity and the citation impact of leading Indian institutions; the media of communication and the characteristics of the high cited publications.
INTRODUCTION
Mental disorders are classifi ed as a psychological condition marked primarily by sufficient disorganization of personality, mind, and emotions to seriously impair the normal psychological and often social functioning of the individual. Antipsychotic medications, introduced in the 1950's, is also widely used to treat some types of mental distress, mainly schizophrenia and manic depression (bipolar disorder), agitation associated with dementia, anxiety disorder, autism spectrum disorder, obsessiveAtypical antipsychotic drugs in India: A scientometric study during 1998-2013 M Ahmed 1 , Ritu Gupta 2 , BM Gupta that these medicines have an effect on. By altering the effects of these chemicals in the brain they can suppress or prevent you from experiencing: Hallucinations (such as hearing voices), delusions (having ideas not based on reality), thought disorder and extreme mood swings that are associated with bipolar disorder. 3 The development of antipsychotics over the last 60 years has come full circle. The first wave of effective antipsychotics was serendipitously discovered in the 1950s and had multiple mechanisms of action. The second wave (e.g. haloperidol) was rationally developed to have a specifi c and selective mechanism of action-dopamine D2 receptor blockade. The third wave completed the circle in that the newest antipsychotics ("atypical" antipsychotics) also have multiple mechanisms of action; specifi cally, they combine blockade of certain subtypes of serotonin (fi ve hydroxytryptamine) receptors and blockade of the D2 receptor. In contrast to the fi rst wave, the third wave was rationally designed to have multiple mechanisms of action. 4 The 1990s saw the development of several new drugs called "atypical antipsychotics (AAP)" or "second generation antipsychotics" (SGAs) for controlling mental diseases. Because they have fewer side-effects than the older drugs, today they are often used as a fi rst-line treatment. The first AAP, clozapine (clozaril), was introduced in the United States in 1989. Since then, six other AAPs have been introduced: Risperidone (1993), olanzapine (1996) , quetiapine (1997), ziprasidone (2001), aripiprazole (2002) , and paliperidone (2006), and several others followed them. 5 The group of atypical antipsychotic drugs (AADs) also have received regulatory approval (e.g. by the Food and Drug Administration of the US, the Therapeutic Goods Administration, of Australia, the Medicines and Healthcare products Regulatory Agency of the UK) for schizophrenia, bipolar disorder, autism and as an adjunct in major depressive disorder. 5 The advances achieved in the fi eld of antipsychotic drugs in the past 20 years have been incredibly important, with the clinical introduction of numerous SGAs (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, etc.), which have notably improved the quality of life of psychotic patients and have contributed decisively to weakening the stigmatization that has traditionally accompanied psychiatric attention. With the clinical introduction of the new SGAs, research related to these drugs has advanced considerably, and this has led to a considerable growth in the publications on these drugs world-wide as well as in India. 6 The present study, therefore, quantitative analyzes the trends of research and characteristics of literature in the area of AADs in India. Research in these publications have been carried output on different parameters including the growth, global publication share, citation impact, share of international collaborative publications, contribution of major collaborative partners, contribution of various subject fi elds and by type of research, productivity and citation impact of most productive Indian organizations and authors and pattern of research communication.
Objectives
The main objectives of the present study are to analyze the research performance of Indian research in AADs during 1998-2013, based on publications indexed in Scopus database. In particular, the study focuses on the following objectives: (i) To study the global research output and its growth; (ii) to study the contribution and citation impact of top 15 most productive countries; (iii) to examine the distribution of citations of the Indian research output; (iv) to study the share of international collaboration publications in Indian publication output and by the leading collaborating partners; (v) to study the distribution of Indian research output by broad subject areas; (vi) to study the distribution of Indian publications output by individual drugs and by disease; (vii) to study the publication productivity and the citation impact of leading institutions; (viii) to study the media of communication; and (ix) to study the characteristics of the high cited publications.
METHODOLOGY
The study retrieved the global publication data and of top 15 most productive countries in AADs from the Scopus database (http://www.Scopus.com) for 16 years during 1998-2013. The keyword "AAP" and "names of 15 AADs" were used in "title, abstract and keyword" fi eld and "1998-2013" in the time fi eld (as shown in following search strategy) was used for searching the main publication data used in the study and this become the main search string. Similar strings were used to generate publications output data of top 15 countries, including India by restricting the main search strategy to particular "country code" tag. For generating citation impact data, the 3 years, 2 years, 1 year citation window was used for publications during 1998-2011, 2012 and 2013. And the citation time was restricted until the end of April 2014. For analyzing institutional and journals output, the main search strategy was restricted to "institutional tag" and "journal tag" to generate the desired output.
[TITLE-ABS-KEY ("AAP") or TITLE-ABS-KEY (clozapine or risperidone or quetiapine) or TITLE-ABS-KEY (aripiprazole or amisulpride or ziprasidone) or TITLE-ABS-KEY (paliperidone or asenapine or iloperidone) or TITLE-ABS-KEY (blonanserin or zotepine or lurasidone) or TITLE-ABS-KEY (sertindole or perospirone or olanzapine)] and PUB YEAR >1997 and PUB YEAR <2014.
ANALYSIS

Global publication output, share, and rank
The global publication share of top 15 most productive countries in AADs in India varied from 1.79% to 36.01% during 1998-2013, with USA occupying the fi rst rank and contributing the largest publication share (36.01%), followed by UK (9.06%, 2 nd rank), Germany(7.17%, 3 rd rank), Canada (5.56%, 4 th rank), Italy (4.68%, 5 th rank), Germany, France, Italy and India (from 4.05% to 4.63% publication share and rank from 6 th to 9 th ), India and The Netherlands (from 2.5% to 2.86% publication share and rank from 10 th to 11 th ) and Turkey, China, Switzerland and Belgium (from 1.60% to 1.90% publication share and rank from 12 th to 15 th ). The global publication share has witnessed the largest increase of 2.90% in India, followed by China (1.64%), Turkey (1.42%), Italy (1.21%), Australia (1.12%), Japan (1.06%), Belgium (1.04%), Spain (1.01%), Canada (0.8%), The Netherlands (0.6%) and Switzerland (0.28%), as against decrease by 1.08% in USA, followed 
Citation pattern of Indian research output
Citations of publications since their publication were examined from 1998 to April 2014. During this period, 9046 citations were received by 1432 publications, and the average rate of citations per publication is 6.32.35.89% of the total publications did not get any citations (zero citation) and the rest of the 64.11% publications were cited one or more times. Of the total cited publications, 0.84% publications (receiving more than 100 citations) contributed 22.71% citations share, 0.56% publications (receiving citations from 51 to 100) contributed 5.83% citations share, 2.58% publications (receiving citations from 31 to 50) contributed 15.65% citations share, 11.03% publications (receiving citations from 11 to 30) contributed 30.07% citations, and the rest 49.090% publications (receiving citations from 1 to 10) contributed 35.89% citations share (Table 3) .
International collaboration
The share of international collaborative publications in total Indian publication output in AADs during was 11.24% (161 publications) during 1998-2013, which decreased from 13.66% (25 publications) during 1998-2005 to 10.89% (136 publications) during 2006-2013. In all 83 foreign countries collaborated with India, as refl ected in India's collaborative publications during 1998-2013. During this period, United States contributed the largest share (49.69%) of international collaborative publications with India, followed by UK (26.09%), Australia (16.77%), Canada (8.70%), Malaysia (7.45%), Israel (6.83%), China (6.83%), Germany, South Korea, Switzerland and Thailand (6.21% each), Japan and Singapore (5.59% each), etc. India's international collaborative publication share has increased by 10.29% in Canada, followed by Malaysia (7.45%), Switzerland and Thailand (7.35% each), Japan and Singapore (6.62% each), China (3.35%), South Korea (2.62%), UK (2.47%0, USA (2.0%) and Australia (0.91%), as against decrease in Israel by 6.12% and in Germany by 2.12% from 1998-2005 to 2006-2013 (Table 4) .
Subject-wise distribution
The India's publication output in AADs research during 1998-2013 has been published in the context of six sub-fi elds (as refl ected in Scopus database classifi cation), with highest publication output coming from medicine (871 publications, 60.82% share), followed by pharmacology, toxicology and pharmaceutics (536 publications, 37.43%), neurosciences (177 publications, 12.36%), chemistry (159 publications, 11.10%), biochemistry, genetics and molecular biology (147 publications, 10.27%) and psychiatry and psychology (101 publications, 7.05%) during 1998-2013. (Table 5) . (Table 6 ).
Drug-wise distribution of publications
Disease-wise distribution of publications
The Indian publications in AADs were studied according to the disease focused. The maximum number of dr ug publications were focused on schizophrenia (524 publications), followed by depression (216 publications), bipolar disorder (194 publications), movement disorder (146 publications), anxiety disorder (141 publications), insomnia (59 publications), dementia (43 publications), delirium (42 publications), personality disorders (26 publications), autism (15 publications) and post-traumatic stress disorder (4 publications) during 1998-2013. The drug-wise break-up of publications under these diseases are shown in Table 7 .
Scientometric profile of top 20 most productive Indian organizations
The total Indian research output in AADs was published from several organizations, of which the top 15 most productive Indian organizations have published 14-206 publications each during 1998-2013 and together contributed 50.21% (719 publications) share in the cumulative Indian publications. The scientometric profi le of these 15 Indian organizations is presented in (Table 9 ).
High cited publications
There are 12 high cited publications which have received more than 100 citations since the publication of the paper Olanzapine (26) Amisulpride (63) Amisulpride (21) Risperidone (22) Paliperidone (16) Paliperidone (3) Clozapine (10) Asenapine (2) Asenapine (2) Quetiapine (10) Iloperidone (4) Iloperidone (3) Aripiprazole (4) Zotepine (6) Zotepine (3) Ziprasidone (3) Blonanserin (2) Blonanserin (1) Blonanserin (1) Lurasidone (2) Lurasidone (1) Personality disorders (26 publications)
Olanzapine (11) Perospirone (4) Anxiety disorder (141 publications)
Olanzapine (64) Risperidone (13) Depression (216 publications)
Olanzapine (105) Risperidone (77) Clozapine (7) Risperidone (106) Clozapine (40) Quetiapine (9) Clozapine (60) Quetiapine (34) Aripiprazole (4) Quetiapine (59) Aripiprazole (28) Ziprasidone (3) Aripiprazole (33) Ziprasidone (16) Amisulpride (2) Ziprasidone (28) Amisulpride (15) Paliperidone (4) Amisulpride (24) Paliperidone (4) Autism (15 publications)
Risperidone (12) Asenapine (2) Clozapine (9) Iloperidone (3) Aripiprazole ( Olanzapine (2) Quetiapine (50) Quetiapine (16) Risperidone (2) Aripiprazole (29) Aripiprazole (13) Ziprasidone (18) Ziprasidone (10) Amisulpride (14) Paliperidone (4) Asenapine (3) Blonanserin (3) Lurasidone (9) AADs: Atypical antipsychotic drugs until April 2014. These 12 high cited publications together received 2054 citations registering an average citation per paper of 171.17. These 12 publications have received citations in the range of: 304-359 (two publications), 152-184 (three publications) and 108-135 (four publications). Of the 12 high cited publications, fi ve are reviews and seven articles. These 12 high cited publications are published in eight professional journals: Journal of Controlled Release (fi ve publications), Lancet, World Psychiatry, British Journal of Psychiatry, Biological Psychiatry, Pharmacological Research, European Nueropsychopharmacology and Crystal Growth and Design (one paper each). The 12 high cited publications involve 20 Indian organizations, including Kakatiya University, University College of Pharmaceutical Science, Warangal (two publications), Reliance Life Sciences Pvt. Ltd., Mumbai (one paper), NIMHANS, Bangalore (one paper), Sangath Center, Goa (one paper), Medical College, Jaipur (one paper), Panjab University, University Institute of Pharmaceutical Science, Chandigarh (one paper), National Institute of Pharmaceutical Education and Research, Mohali (one paper), etc. The 12 high cited publications involve fi ve international collaborative publications and two national collaborated publications (Table 10 ).
SUMMARY
In AADs research, India has produced 1432 publications during 1998-2013, which increased from 9 to 216 publications from the year 1998-2013, registering an annual average growth rate of 22.76%. India's global publication rank was 10 th among the 15 most productive countries with global publication share of 2.86% during 1998-2012. India's global publication share and rank increased from 1.01% to 3.91% and from 12 th to 8 th from 1998-2005 to 2006-2013. The citation impact per paper registered by Indian publications in AADs was 2.43, which decreased from 3.14 to 2.32 from 1998-2005 to 2006-2013. Of the total publications, 35.89% of the total publications did not get any citations (zero citation) and 64.11% publications were cited one or more times. Of the cited publications, only 0.84% of the publications (receiving more than 100 citations) contributed 22.71% citations share, as against 49.090% publications (receiving citations from 1 to 10) contributing 35.89% citations share. Only 11.24% of the total Indian publications were internationally collaborative during 1998-2013, which decreased from 13.66% to 10.89% from 1998-2005 to 2006-2013. Among the leading foreign collaborative partners, USA contributed the largest share of 49.69% during 1998-2013, followed by UK (26.09%), Australia (16.77%), Canada (8.70%), Malaysia (7.45%), Israel (6.83%), China (6.83%), etc. Among the subjects, medicine contributed the largest share of 60.82% during 1998-2013, followed by pharmacology, toxicology and pharmaceutics (37.43%), neurosciences (12.36%), chemistry (11.10%), biochemistry, genetics and molecular biology (10.27%) and psychiatry and psychology (7.05%). Research activity has increased in medicine, pharmacology, toxicology and pharmaceutics, neurosciences and chemistry, as against decrease in biochemistry, genetics and molecular activity and psychiatry and psychology from 1998-2005 to 2006-2013. The most widely studied drug was olanzapine with 42.11% publication share, followed by risperidone (37.92%), clozapine (25.07%), quetiapine (17.04%), aripiprazole (11.31%), ziprasidone (7.75%), amisulpride (6.91%), paliperidone (3.21%), asenapine (1.40%), iloperidone (0.98%), zotepine (0.63%), blonanserine (0.35%), lurasidone (0.24%) and perospirone (0.24%) during 1998-2013. The research interest in the use of these drugs have increased in quetiapine, aripiprazole, ziprasidone, amisulpride, paliperidone, asenapine, iloperidone, zotepine and blonanserine, as against decrease in olanzapine, risperidone, clozapine, lurasidone and perospirone from 1998-2005 to 2006-2013. Among the diseases reported for the use of these drugs, the largest number of publications (524) were in schizophrenia, followed by depression (216 publications), bipolar disorder (194 publications), movement disorder (146 publications), anxiety disorder (141 publications), insomnia (59 publications), dementia (43 publications), delirium (42 publications), personality disorders (26 publications), autism (15 publications) and post-traumatic stress disorder (4 publications) during 1998-2013. The top 15 most productive Indian organizations together account for 50.21% (719 publications) share to the cumulative Indian publications output in AADs research during 1998-2013. The largest number of publications (206 publications) were contributed by NIMHANS, Bangalore, followed by Central Institute of Psychiatry, New Delhi (98 publications) and PGIMER, Chandigarh (95 publications), etc. Among various journals contributing to AADs research, the top 15 foreign and Indian journals contributed accounts for 23.95% and 18.02% share of the total Indian publications during 1998-2013. The share of Indian publications in foreign journals has increased from 22.95% to 24.10%, in contrast to decrease in Indian journals from 18.03% to 18.01% from 1998-2005 to 2006-2013.
